From bench to GMP: key criteria and operational readiness considerations for selecting a CGT biomanufacturing partner

 

Manufacturing readiness is a crucial determinant of clinical timelines. This paper presents a practical framework grounded in operational experience for evaluating project preparedness, defining manufacturing partner selection criteria, and identifying process-integrated capabilities that reduce variability and support regulatory readiness.

What you will learn

01

A developer readiness checklist covering documentation, materials, QMS maturity, and starting material strategy, and how preparedness level correlates with manufacturing timeline outcomes

02

Seven manufacturing partner selection criteria evaluated through real-world manufacturing case studies, covering technology transfer, facility design, quality systems, regulatory alignment, and analytics integration

03

How integrated starting material control and co-developed analytics differ operationally from externally sourced CDMO models and the practical implications for batch consistency and regulatory readiness

The BSO development pathway

1

Technology Transfer

2

Process Development

3

MSAT & GMP Scale-up

4

Quality & Regulatory

5

Clinical & Commercial

Key findings

Projects entering GMP manufacturing without established CQAs, traceable documentation, and standardized assays experience recurring deviations and timeline extensions

In a reported leukopak case study, upstream adjustments to donor screening and apheresis parameters — enabled by internal starting material control — improved expansion consistency without adding downstream processing steps

Analytical assays developed in parallel with process development, rather than retrofitted post-optimisation, support earlier detection of CQA deviations and reduce the risk of late-stage method redesign ahead of regulatory submissions

Key interests

Cell Therapy Gene Delivery Gene Therapy

Please enter your email to access content Read now